6-(4-bromophenyl)-5-(4-methylphenyl)-1-phenyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one | 439136-54-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 6-(4-bromophenyl)-5-(4-methylphenyl)-1-phenyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
• 英文别名: 6-(4-bromophenyl)-5-(4-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one
• CAS: 439136-54-6
• 化学式: C₂₄H₁₇BrN₄O
• mdl: MFCD02928064
• 分子量: 457.329
• InChiKey: MMEHYYYPJXTOED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  50.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  、 5-氨基-4-乙氧羰基-1-苯基吡唑 在 四氯化钛 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 0.33h， 以79%的产率得到6-(4-bromophenyl)-5-(4-methylphenyl)-1-phenyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
  参考文献：
  名称：

  路易斯酸辅助环化反应高效合成稠合双环2,3-二芳基-嘧啶-4（3 H）-

  摘要：

  描述了一种方便的一锅合成法，它由三种容易获得的组分合成稠合的双环2，3-二芳基-嘧啶-4（3 H）-。关键步骤是路易斯酸辅助环化反应。

  DOI：

  10.1016/j.tetlet.2008.01.071

文献信息

• COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY
  申请人：Liu Hong

  公开号：US20090247517A1

  公开（公告）日：2009-10-01

  The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).

  本发明提供了化合物、包含这些化合物的制药组合物以及使用这些化合物治疗或预防与大麻素受体1（CB1）的活性有关的疾病或紊乱的方法。
• COMBINATION OF ORGANIC COMPOUNDS
  申请人：Novartis AG

  公开号：EP1791600A1

  公开（公告）日：2007-06-06
• Combination of Organic Compounds
  申请人：Maher William

  公开号：US20070299047A1

  公开（公告）日：2007-12-27

  The present invention relates to a pharmaceutical composition, comprising a PPAR agonist, or pharmaceutically acceptable salts thereof, alone or in combination with at least one active ingredient selected from the group consisting of (i) HDL increasing compounds; (ii) anti-diabetics; (iii) an anti-hypertensive agent; (iv) cholesterol absorption modulator; (v) apo-A1 analogs and mimetics; (vi) renin inhibitors; (vii) thrombin inhibitors; (viii) aldosterone inhibitors; (ix) GLP-1 agonists; (x) glucagon receptor antagonists; (xi) cannabinoid receptor 1 antagonists; (xii) anti-obesity agents; and (xiii) inhibitors of platelet aggregation or, in each case, a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable carrier.
• US8158634B2
  申请人：——

  公开号：US8158634B2

  公开（公告）日：2012-04-17
• [EN] COMBINATION OF ORGANIC COMPOUNDS<br/>[FR] COMBINAISON DE COMPOSES ORGANIQUES
  申请人：NOVARTIS AG

  公开号：WO2006029349A1

  公开（公告）日：2006-03-16

  The present invention relates to a pharmaceutical composition, comprising a PPAR agonist, or pharmaceutically acceptable salts thereof, alone or in combination with at least one active ingredient selected from the group consisting of (i) HDL increasing compounds; (ii) anti-diabetics; (iii) an anti-hypertensive agent; (iv) cholesterol absorption modulator; (v) apo-A1 analogs and mimetics; (vi) renin inhibitors; (vii) thrombin inhibitors; (viii) aldosterone inhibitors; (ix) GLP-1 agonists; (x) glucagon receptor antagonists; (xi) cannabinoid receptor 1 antagonists; (xii) anti-obesity agents; and (xiii) inhibitors of platelet aggregation or, in each case, a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable carrier. The pharmaceutical composition may be employed for the treatment of addictions (for example, nicotine and cocaine), dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, stroke, intermittent claudication, restenosis after PCTA, hypertension, obesity including reduction in CV risk in obese patients, inflammation, arthritis, cancer including breast, colon and prostate cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, IBDs (irritable bowel disease), Crohn's disease, hypofibrinolysis, hypercoaguable state, metabolic/cardiometabolic syndrome, elevated CRP, appearance of microalbuminuria, reduction of proteinuria, renal failure (DM, non-DM), NASH (non alcoholic steato hepatitis) non-alcoholic fatty liver, CV events in patients with high CRP, vascular dementia, psoriasis, ischaemia reperfusion injury, asthma, COPD, eosinophilia, RA, airway hyperresponsiveness (AHR), inflammatory digestive diseases (e.g. ulcerative colitis) diseases of anitgen-induced inflammatory responses. The compounds of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions such as impaired glucose tolerance, hyperglycemia, insulin resistance, type-1 and type-2 diabetes and Syndrome X. Also contemplated is the administration of the combinations of the present invention for the improvement of cardiac metabolism and cardioprotection in heart transplant patients, to facilitate smoking cessation or reduction and to prevent or treat conditions associated with smoking.